› 5lmb

X-ray diffraction
1.95Å resolution

HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR

Released:
DOI: 10.2210/pdb5lmb/pdb
PDB entry 5lmb coloured by chain, front view.
PDB entry 5lmb coloured by chain, side view.
PDB entry 5lmb coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Optimisation of a novel series of potent and orally bioavailable azanaphthyridine SYK inhibitors.
Garton NS, Barker MD, Davis RP, Douault C, Hooper-Greenhill E, Jones E, Lewis HD, Liddle J, Lugo D, McCleary S, Preston AGS, Ramirez-Molina C, Neu M, Shipley TJ, Somers DO, Watson RJ, Wilson DM
Bioorg Med Chem Lett 26 4606-4612 (2016)
PMID: 27578246

Function and Biology Details

Reaction catalysed: 
ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate
Biochemical function:
Biological process:
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
monomeric (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-155056 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecule:
Tyrosine-protein kinase SYK Chains: A, B
Molecule details ›
Chains: A, B
Length: 277 amino acids
Theoretical weight: 32.16 KDa
Source organism: Homo sapiens
Expression system: Spodoptera frugiperda
UniProt:
  • Canonical: P43405 (Residues: 360-635; Coverage: 44%)
Gene name: SYK
Sequence domains: Protein tyrosine and serine/threonine kinase
Structure domains:

Ligands and Environments

2 bound ligands:
Ligand 6ZF 2 x 6ZF
Ligand GOL 7 x GOL
1 modified residue:
Ligand PTR 2 x PTR

Experiments and Validation Details

Entry percentile scores
X-ray source: ESRF BEAMLINE ID23-1
Spacegroup: P1
Unit cell:
a: 39.849Å b: 41.78Å c: 86.991Å
α: 99.81° β: 90.41° γ: 100.03°
R-values:
R R work R free
0.178 0.175 0.228
Expression system: Spodoptera frugiperda

Quick links

Citations

2 citation in other articles

GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin.
Ramirez Molina et al. (2019)
1 more